<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Anthracyclines; Doxorubicin; Leukaemia: acute; Epirubicin; Idarubicin; Daunorubicin; Mitoxantrone; Bleomycin; Dactinomycin; Mitomycin" /><meta name="IX" content="Anthracyclines; Doxorubicin; Leukaemia: acute; Epirubicin; Idarubicin; Daunorubicin; Mitoxantrone; Bleomycin; Dactinomycin; Mitomycin" /><title>8.1.2 Anthracyclines and other cytotoxic antibiotics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5282-anthracyclines-and-other-cytotoxic-antibiotics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5282-anthracyclines-and-other-cytotoxic-antibiotics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5282-anthracyclines-and-other-cytotoxic-antibiotics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5279-treosulfan.htm" title="Previous: TREOSULFAN">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5301-bleomycin.htm" title="Next: BLEOMYCIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>8.1.2 </span>Anthracyclines and other cytotoxic antibiotics</h1><?highlighter on?><div id="pC" class="jN"><p id="PHP5283">Drugs in this group are widely used. Many cytotoxic antibiotics act as radiomimetics and simultaneous use of radiotherapy should be <strong>avoided</strong> because it may markedly increased toxicity.</p> <p><strong>Daunorubicin</strong>, <strong>doxorubicin</strong>, <strong>epirubicin</strong> and <strong>idarubicin</strong> are anthracycline antibiotics. Mitoxantrone is an anthracycline derivative.</p> <p id="PHP5284"><strong>Doxorubicin</strong> is used to treat the acute leukaemias, Hodgkin's and non-Hodgkin's lymphomas, paediatric malignancies, and some solid tumours including breast cancer. It is given by injection into a fast-running infusion, commonly at 21-day intervals. Extravasation can cause severe tissue necrosis. Doxorubicin is largely excreted in the bile and an elevated bilirubin concentration is an indication for reducing the dose. Diarrhoea, dehydration, and red coloration of the urine can commonly occur, and renal damage has been reported. Supraventricular tachycardia related to drug administration is an uncommon complication. Higher cumulative doses are associated with cardiomyopathy and it is usual to limit total cumulative doses to 450 mg/m<sup>2</sup> because symptomatic and potentially fatal heart failure is common above this dose. Patients should be assessed before treatment by echocardiography; the elderly, and those with cardiac disease, hypertension, or who have received myocardial irradiation, should be treated cautiously. Cardiac monitoring may assist in determining safe dosage. Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility. Some evidence suggests that weekly low-dose administration may be less cardiotoxic. Doxorubicin is also given by bladder instillation for the treatment of transitional cell carcinoma, papillary bladder tumours and carcinoma <em>in-situ</em>. </p> <p id="PHP5288">Liposomal formulations of doxorubicin for intravenous use are also available. They may reduce the incidence of cardiotoxicity and lower the potential for local necrosis, but infusion reactions, sometimes severe, may occur. Hand-foot syndrome (painful, macular reddening skin eruptions) occurs commonly with liposomal doxorubicin and may be dose limiting. It can occur after 2–3 treatment cycles and may be prevented by cooling hands and feet and avoiding socks, gloves, or tight-fitting footwear for 4–7 days after treatment.</p> <div class="cI"><h3 class="cT">NICE guidance (paclitaxel, pegylated liposomal doxorubicin and topotecan for second-line or subsequent treatment of advanced ovarian cancer)</h3><p>See <a title="target-block: paclitaxel, doxorubicin, topotecan nice guidance" href="PHP5487-platinum-compounds.htm#PHP5496">Platinum Compounds</a></p></div> <p id="PHP5289"><strong>Epirubicin</strong> is structurally related to doxorubicin and clinical trials suggest that it is as effective in the treatment of breast cancer. A maximum cumulative dose of 0.9–1 g/m<sup>2</sup> is recommended to help avoid cardiotoxicity. Like doxorubicin it is given intravenously and by bladder instillation. Hyperpigmentation of skin, nails, and oral mucosa, and red coloration of the urine, may occur.</p> <p id="PHP5291"><strong>Idarubicin</strong> has general properties similar to those of doxorubicin; it is mostly used in the treatment of haematological malignancies. Diarrhoea, abdominal pain, haemorrhage, cardiac disorders, rash, and red pigmentation of the urine are commonly reported. Skin and nail hyperpigmentation have been reported less frequently. Idarubicin is given intravenously and it may also be given by mouth.</p> <p id="PHP5292"><strong>Daunorubicin </strong> also has general properties similar to those of doxorubicin. It should be given by intravenous infusion and is indicated for acute leukaemias. A liposomal formulation for intravenous use is licensed for AIDS-related Kaposi's sarcoma.</p> <div class="cI"><h3 class="cT">Use with trastuzumab</h3><p>Concomitant use of anthracyclines with trastuzumab (section 8.1.5) is associated with cardiotoxicity; for details, see <a title="target-block: use with anthracyclines" href="PHP5578-trastuzumab.htm#PHP5580">Use with anthracyclines</a>.</p></div> <p id="PHP5294"><strong>Mitoxantrone</strong> is structurally related to doxorubicin; it is used for metastatic breast cancer. Mitoxantrone is also licensed for treatment of non-Hodgkin's lymphoma, adult acute non-lymphocytic leukaemia, and non-resectable primary hepatocellular carcinoma. It is given intravenously and is well tolerated, but myelosuppression and dose-related cardiotoxicity occur; cardiac examinations are recommended after a cumulative dose of 160 mg/m<sup>2</sup>.</p> <p id="PHP5296"><strong>Bleomycin</strong> is given intravenously or intramuscularly to treat metastatic germ cell cancer and, in some regimens, non-Hodgkin's lymphoma. It causes little bone-marrow suppression but dermatological toxicity is common and increased pigmentation particularly affecting the flexures and subcutaneous sclerotic plaques may occur. Mucositis is also relatively common and an association with Raynaud's phenomenon is reported. Hypersensitivity reactions manifest by chills and fevers commonly occur a few hours after drug administration and may be prevented by simultaneous administration of a corticosteroid, for example hydrocortisone intravenously. The principal problem associated with the use of bleomycin is progressive pulmonary fibrosis. This is dose-related, occurring more commonly at cumulative doses greater than 300 000 units (see Bleomycin, below) and in the elderly. Basal lung crepitations or suspicious chest X-ray changes are an indication to stop therapy with this drug. Patients who have received extensive treatment with bleomycin (e.g. cumulative dose more than 100 000 units—see Bleomycin below) may be at risk of developing respiratory failure if a general anaesthetic is given with high inspired oxygen concentrations. Anaesthetists should be warned of this.</p> <p id="PHP5298"><strong>Dactinomycin </strong> is principally used to treat paediatric cancers; it is given intravenously. Its side-effects are similar to those of doxorubicin, except that cardiac toxicity is not a problem.</p> <p id="PHP5299"><strong>Mitomycin </strong> is given intravenously to treat upper gastro-intestinal and breast cancers and by bladder instillation for superficial bladder tumours. It causes delayed bone-marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage.</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5301-bleomycin"><a href="PHP5301-bleomycin.htm" title="BLEOMYCIN">BLEOMYCIN</a></li><li id="_PHP5303-dactinomycin"><a href="PHP5303-dactinomycin.htm" title="DACTINOMYCIN">DACTINOMYCIN</a></li><li id="_PHP5306-daunorubicin"><a href="PHP5306-daunorubicin.htm" title="DAUNORUBICIN">DAUNORUBICIN</a></li><li id="_PHP5310-doxorubicin-hydrochloride"><a href="PHP5310-doxorubicin-hydrochloride.htm" title="DOXORUBICIN HYDROCHLORIDE">DOXORUBICIN HYDROCHLORIDE</a></li><li id="_PHP5315-epirubicin-hydrochloride"><a href="PHP5315-epirubicin-hydrochloride.htm" title="EPIRUBICIN HYDROCHLORIDE">EPIRUBICIN HYDROCHLORIDE</a></li><li id="_PHP5319-idarubicin-hydrochloride"><a href="PHP5319-idarubicin-hydrochloride.htm" title="IDARUBICIN HYDROCHLORIDE">IDARUBICIN HYDROCHLORIDE</a></li><li id="_PHP5321-mitomycin"><a href="PHP5321-mitomycin.htm" title="MITOMYCIN">MITOMYCIN</a></li><li id="_PHP5323-mitoxantrone"><a href="PHP5323-mitoxantrone.htm" title="MITOXANTRONE">MITOXANTRONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5279-treosulfan.htm">Previous: TREOSULFAN</a> | <a class="top" href="PHP5282-anthracyclines-and-other-cytotoxic-antibiotics.htm#">Top</a> | <a accesskey="]" href="PHP5301-bleomycin.htm">Next: BLEOMYCIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>